

Research Article

Tin Myo Thant, Nanik Siti Aminah*, Alfinda Novi Kristanti, Rico Ramadhan, Hnin Thanda Aung, Yoshiaki Takaya

New derivatives of a natural nordinatin

<https://doi.org/10.1515/chem-2020-0149>

received February 15, 2020; accepted June 6, 2020

Abstract: New derivatives were obtained from natural nordinatin (**1**) previously isolated from the methanol fraction of *Clausena excavata* by an acylation method. Herein, we report ten new pyranocoumarin derivatives **1a–1j**. Their structures were elucidated based on UV-vis, FT-IR, NMR, and DART-MS data. The α -glucosidase inhibition and anticancer activities of nordinatin (**1**) and its derivatives were also evaluated. The α -glucosidase inhibition assay exhibited that the derivatives **1b**, **1d**, **1e**, **1f**, **1h**, **1i**, and **1j** possess higher inhibitory activity for α -glucosidase with IC_{50} values of 1.54, 9.05, 4.87, 20.25, 12.34, 5.67, and 2.43 mM, whereas acarbose was used as the positive control, $IC_{50} = 7.57$ mM. All derivatives exhibited a weak cytotoxicity against a cervical cancer (HeLa) cell line with the IC_{50} between 0.25 and 1.25 mM. They also showed moderate to low growth inhibition of a breast cancer (T47D) cell line with IC_{50} values between 0.043 and 1.5 mM, but their activity was lower than that of the parent compound, nordinatin (**1**) ($IC_{50} = 0.041$ mM).

Keywords: *Clausena excavata*, pyranocoumarin derivatives, nordinatin, yeast α -glucosidase inhibition, cytotoxicity, cervical cancer, breast cancer

1 Introduction

Clausena excavata Burm f. belongs to the Rutaceae family and grows mainly in south and southeast Asia [1]. The plant is a wild shrub; its leaves, twigs, and root barks are used as traditional medicine for the treatment of cold, malaria, abdominal pain, snake-bite, viral infections (e.g., HIV), and dermatopathy. The plant is reported to contain bioactive constituents with antibacterial, antifungal, antimycobacterial, antinociceptive, *in vivo* immunomodulating, and insecticidal properties. Phytochemical studies have revealed that *C. excavata* is a rich source of coumarins [2,3], carbazole alkaloids [4], and limonoid [5]. Coumarins are plant-derived compounds with a benzopyrone moiety. They possess a wide variety of biological activities. Coumarins and their derivatives are being extensively studied for their biological activities, low toxicity, and low drug resistance properties [6,7].

It has been reported that nordinatin exhibits hypoglycemic activity [8]. The conversion reaction of this compound into its ester derivative is desired, as the derivative is expected to possess more potent biological activities, especially as an antidiabetic medicine in the future. Diabetes mellitus is a chronic disease caused by the dysfunction of carbohydrate metabolism. It has been recognized as one of the most serious public health problems globally. The International Diabetes Federation has estimated that 425 million people worldwide have diabetes. The number will increase to 642 million by 2040 [9–11]. Recently, there has been immense interest in the study of enzymes as drug targets. Especially, the inhibition of α -glucosidase can help in controlling postprandial glucose levels in diabetic patients. α -Glucosidases (α -D-glucoside glucohydrolase EC. 3.2.1.20) are membrane-bound enzymes, located in the epithelium of the small intestine, and the key enzymes of carbohydrate digestion. The inhibitors of α -glucosidase can delay the digestion of starch and other dietary sugars, and thus they prevent the onset of hyperglycemia and maintain the normal blood sugar level [9–11]. Clinical trials have already shown that α -glucosidase inhibitors can improve long-term glycemic

* Corresponding author: Nanik Siti Aminah, Department of Chemistry, Faculty of Science and Technology, Airlangga University, Komplek Kampus C UNAIR, Jl. Mulyorejo, Surabaya, Indonesia, e-mail: nanik-s-a@fst.unair.ac.id, tel: +62-31-593-6501, fax: +62-31-593-6502

Tin Myo Thant: Department of Chemistry, Faculty of Science and Technology, Airlangga University, Komplek Kampus C UNAIR, Jl. Mulyorejo, Surabaya, Indonesia; Department of Chemistry, Mandalay Degree College, Mandalay, Myanmar

Alfinda Novi Kristanti, Rico Ramadhan: Department of Chemistry, Faculty of Science and Technology, Airlangga University, Komplek Kampus C UNAIR, Jl. Mulyorejo, Surabaya, Indonesia

Hnin Thanda Aung: Department of Chemistry, Mandalay University, Mandalay, Myanmar

Yoshiaki Takaya: Department of Pharmacy, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku, Nagoya, 468-8503, Japan

control and decrease hemoglobin A1c (HbA1c) levels in patients with type II diabetes. They can also delay the development of type II diabetes in patients with impaired glucose tolerance [12]. Inhibitors of α -glucosidase such as voglibose, miglitol, and acarbose are currently used clinically, but their use is limited due to their adverse effects, such as diarrhea, abdominal cramping, flatulence, and vomiting. Therefore, much effort has been focused to develop effective α -glucosidase inhibitors from natural sources [13–15].

Cancer, in its various forms, is one of the major causes of death of the human population. Among them, cervical and breast cancers are the most common causes of cancer-related deaths in women globally [15,17]. Several natural products of plant origin could potentially be used as cancer chemotherapeutic agents. Some of the currently used plant-derived anticancer agents include podophyllotoxin, taxol, vincristine, and camptothecin [17]. The conversion reaction of marchantin to its ester derivatives increases the anticancer activity [18]. In the present work, we semi-synthesized pyranocoumarin benzoate derivatives from nordenatin (**1**) by using different benzoyl chlorides. Subsequently, the inhibitory effects of the resulting derivatives and of the parent compound against α -glucosidase enzymes and two cancer cell lines (HeLa and T47D) were evaluated and compared.

2 Materials and methods

2.1 Materials

2.1.1 Materials for synthesis

NMR experiments were performed on Bruker 600 MHz (^1H) and 151 MHz (^{13}C) instruments in CDCl_3 solvent. MS data were recorded on a DART-MS instrument. Melting points were determined on a Stuart (SMP30) instrument. Infrared spectra were recorded on an IR Tracer-100, ν in cm^{-1} . The UV-vis spectra were obtained on a Shimadzu (UV-1800) UV-vis spectrometer. The target compounds (**1a–1j**) were semi-synthesized by an acylation method with slight modification [19,20]. The starting material, nordenatin (**1**), was collected from our previous research [2]. Reagents such as 4-bromobenzoyl chloride, 3-chlorobenzoyl chloride, 2-chloro-4-nitrobenzoyl chloride, 3-chloro-4-fluoro benzoyl chloride, 3-bromo-benzoyl chloride, 4-butylbenzoyl chloride, 2,4,6-trichlorobenzoyl chloride, 3-trifluoromethylbenzoyl chloride, 3,5-bis

(trifluoromethyl)benzoyl chloride, and 4-iodobenzoyl chloride (Wako, Japan) were used for the modification of compound **1** (nordenatin). Pyridine and 4-dimethylamino pyridine were used as catalysts. The reaction products were isolated by column chromatography on silica gel 60 (0.063–0.200 mm; Merck, Germany), by eluting with *n*-hexane and dichloromethane (20–100%). The reaction progress and the purity of the obtained compounds were monitored by p-TLC (preparative thin layer chromatography) on UV-254 plates (*n*-hex: CH_2Cl_2 , 9:1; detection under UV light and by spraying anis aldehyde, followed by heating). The solvents (CH_2Cl_2 , *n*-hex, and EtOAc) were purified by standard methods and distilled just before use.

2.1.2 Materials for antidiabetic and cytotoxic testing

The α -glucosidase from *Saccharomyces cerevisiae* (EC 3.2.1.20), and 4-nitrophenyl α -D-glucopyranoside (*p*-NPG) were obtained from Sigma-Aldrich. Spectrophotometric measurements for the yeast α -glucosidase inhibition were recorded on an i-Mark microplate reader.

The materials used in the cytotoxicity test with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) cell viability assay performed on cervical (HeLa) and breast (T47D) cancer cell lines are as follows: Dulbecco's Modified Eagle's Medium, fetal bovine serum (FBS) 10% (w/v), dimethyl sulfoxide, phosphate buffer solution, MTT, phenazine methosulfate, sodium dodecyl sulfate 10% (w/v), and HCl 0.1 N.

2.2 Methods

2.2.1 General procedure for the modification of nordenatin (**1**) with benzoyl chloride derivatives by an acylation method

Esterification of nordenatin (**1**) was carried out by an acylation method [6,15] (Figure 1). First, around 100 mg of sample (**1**) was put in each flask. It was dissolved by adding 2 mL of pyridine and 10 mg of 4-(dimethylamino)-pyridine (DMAP) to the mixture. Subsequently, the mixture was stirred on a magnetic stirrer, and different kinds of benzoyl chlorides were added slowly. Then, the reaction was allowed to proceed at room temperature for 1 h. The mixture was checked with TLC at 30 min intervals until the reaction was completed. A




Figure 1: Scheme for the semi-synthesis of pyranocoumarin benzoate derivatives.

volume of 30 mL of EtOAc and 30 mL of distilled water were added to the product mixture. Pyridine was neutralized with 1 M concentrated HCl. The mixture was shaken vigorously three times by using a separating funnel and the organic layer was collected. The aqueous layer was exacted three times with 30 mL of EtOAc. The EtOAc portion was combined and dehydrated with brine water and anhydrous magnesium sulfate. The solvent was removed using a rotary evaporator. Finally, the product mixtures were chromatographed and the pure compounds **1a** to **1j** were obtained.

2.2.2 α -Glucosidase inhibition assay

The inhibition activity of all isolated compounds against yeast was determined by the method disclosed by Ramadhan et al. [21] with slight modifications. A sample (10 μ L) was mixed with yeast (0.4 U/mL) in 1 mM phosphate buffer (pH 6.9), followed by shaking with a microplate shaker for 2 min and pre-incubation at 37°C for 10 min. The reaction mixture was added to 50 μ L of *p*-nitrophenyl- α -D-glucopyranoside (*p*-NPG). Subsequently, the mixture was placed in an incubator at 37°C for 20 min. After the incubation, the reaction was quenched by adding Na₂CO₃ (100 μ L). The release of *p*-nitrophenoxide from *p*-NPG was detected with a microplate reader at 415 nm (i-Mark ELISA [enzyme-linked immunosorbent assay] reader). Inhibition of the reaction was calculated using $[(A_0 - A_1)/A_0] \times 100$, where A_0 is the absorbance without the sample and A_1 is the absorbance with the sample. The IC₅₀ value was determined from a plot of percentage inhibition versus sample concentration. Acarbose was used as the standard control, and the experiment was performed in triplicate.

2.2.3 MTT assay

The cytotoxicity of parent compound (**1**) and modified compounds (**1a-1j**) was measured by using the MTT

assay method following the protocol of Suwito et al [22]. The cancer cells were seeded in a 96-well plate at a density of 1×10^4 cells/well with a phenol red-free RPMI (Roswell Park Memorial Institute) 1640 medium (containing 10% FBS) and kept for 24 h. Subsequently, the tested compound (various concentrations) was applied for 24 h. After addition of 0.5% MTT solution, the incubation was continued for a further 4 h at 37°C/5% CO₂. The stop solution (0.04 N HCl in isopropanol) was added to the culture medium in each well. The spectroscopic measurements were carried out at 570 nm (peak) and 630 nm (bottom) using an ELISA reader. The experiment was conducted in triplicate. Doxorubicin was used as a positive control.

Ethical approval: The conducted research is not related to either human or animal use.

3 Results and discussion

3.1 Semi-synthesis

In this study, derivatization of nordinatin (**1**) was carried out by using various benzoyl chlorides (Figure 1). The reaction was simple, quick, and has resulted in ten new pyranocoumarin benzoates (**1a-1j**) (Figure 2). Their structures were not only elucidated based on spectroscopic data but also compared with the structure of nordinatin (**1**) (Figures S1-S46). The FT-IR spectral data supported the presence of the -OH stretching group broad band in compound **1**, and the absence of -OH stretching in compounds **1a-1j**. In addition, the ¹³C-NMR spectral data revealed the presence of one more carbonyl carbon from the benzoyl group at $\delta_c \sim 161$ ppm. The presence of fluoro-containing compounds was inferred from splitting patterns and coupling constants in ¹³C-NMR.




Figure 2: Structures of derivatives **1a–1j** from nordentatin (**1**).

3.1.1 Spectral data of compound **1a**, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H*,8*H*-pyrano[3,2-*g*]chromen-5-yl 4-bromobenzoate

Nordentatin (108.2 mg, 0.3467 mmol), 4-bromobenzoyl chloride (121.6 mg, 0.5500 mmol), yield 43.2%. UV (MeOH), λ_{max} (log ε) 349 (0.79), 257 (2.87), 231 (1.0). M.p. 203–206°C. FT-IR 3,080, 2,972, 2,929, 2,873, 1,747, 1,730, 1,641, 1,618, 1,552 cm^{-1} . ^1H NMR (chloroform-*d*, 600 MHz) δ 2 \times 8.11 (1H, d, J = 8.7 Hz), 2 \times 7.72 (1H, d, J = 8.7 Hz), 7.53 (1H, d, J = 9.7 Hz), 6.33 (1H, dd, J = 17.4, 10.6 Hz), 6.26 (1H, d, J = 10.0 Hz), 6.19 (1H, d, J = 9.7 Hz), 5.69 (1H, d, J = 10.0 Hz), 4.98 (1H, dd, J = 17.4, 1.0 Hz), 4.92 (1H, dd, J = 10.6, 1.0 Hz), 2 \times 1.70 (3H, s), 2 \times 1.47 (3H, s). ^{13}C NMR (151 MHz, chloroform-*d*), δ 163.7, 160.1, 155.6, 2 \times 153.8, 149.5, 141.2, 137.8, 132.4, 131.8, 131.8,

129.9, 126.8, 121.3, 115.6, 112.8, 112.0, 108.5, 2 \times 107.2, 77.9, 41.4, 2 \times 29.4, 2 \times 27.7. DART-MS, $\text{C}_{26}\text{H}_{24}\text{BrO}_5$ [$\text{M} + \text{H}$]⁺, *m/z*: 495.0805 (calcd mass for $\text{C}_{26}\text{H}_{24}\text{BrO}_5$, *m/z*: 495.0807), $\text{C}_{26}\text{H}_{24}^{81}\text{BrO}_5$ [$\text{M} + \text{H}$]⁺, *m/z*: 497.0784.

3.1.2 Spectral data of compound **1b**, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H*,8*H*-pyrano[3,2-*g*]chromen-5-yl 3-chlorobenzoate

Nordentatin (107.4 mg, 0.3442 mmol), 3-chlorobenzoyl chloride (90.3 mg, 0.5163 mmol), yield 74.9%, λ_{max} (log ε) 340 (0.772), 268 (1.703), 233 (1.952), 233 (1.952). M.p. 173–174°C. FT-IR 3,080, 2,964, 2,922, 2,852, 1,743, 1,724, 1,620, 1,602, 1,554 cm^{-1} . ^1H NMR (chloroform-*d*, 600 MHz) δ 8.33 (1H, dd, J = 6.9, 2.1 Hz), 8.16 (1H, ddd, J = 8.5, 4.5,

2.2 Hz), 2 \times 7.52 (1H, d, J = 9.7 Hz), 7.34 (1H, t, J = 8.5 Hz), 6.33 (1H, dd, J = 17.4, 10.6 Hz), 6.24 (1H, d, J = 10.0 Hz), 6.20 (1H, d, J = 9.7 Hz), 5.71 (1H, d, J = 10.0 Hz), 4.98 (1H, d, J = 17.4 Hz), 4.92 (1H, m), 1.70 (6H, s), 1.48 (6H, s). ^{13}C NMR data (see the supplementary material). DART-MS, $\text{C}_{26}\text{H}_{24}\text{ClO}_5$, m/z : 451.1313 [M + H]⁺ (calcd mass for $\text{C}_{26}\text{H}_{24}\text{ClO}_5$, m/z : 451.1312), $\text{C}_{26}\text{H}_{24}^{37}\text{ClO}_5$ [M + H]⁺, m/z : 453.1286.

3.1.3 Spectral data of compound 1c, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H,8H*-pyrano[3,2-*g*]chromen-5-yl 2-chloro-4-nitrobenzoate

Nordentatin (115.6 mg, 0.3686 mmol), 2-chloro-4-nitrobenzoyl chloride (121.6 mg, 0.5500 mmol), yield 43.6%. UV (MeOH), λ_{\max} (log ϵ) 340 (0.509), 267 (1.468). M.p. 197–198°C. FT-IR 3,105, 3,088, 2,995, 2,968, 2,933, 1,762, 1,720, 1,618, 1,535 cm⁻¹. ^1H NMR (chloroform-*d*, 600 MHz) δ 8.45 (1H, m), 8.29 (2H, d, J = 1.0 Hz), 7.60 (1H, d, J = 9.7 Hz), 6.32 (2H, m), 6.24 (1H, d, J = 9.7 Hz), 5.76 (1H, d J = 9.7 Hz), 4.98 (1H, dd, J = 17.4, 0.9 Hz), 4.92 (1H, dd, J = 10.6, 0.9 Hz), 1.70 (6H, s), 1.49 (6H, s). ^{13}C NMR data (see the supplementary material). DART-MS, $\text{C}_{26}\text{H}_{23}\text{ClNO}_7$, m/z : 496.1162 [M + H]⁺ (calcd mass for $\text{C}_{26}\text{H}_{23}\text{ClNO}_7$, m/z : 496.1163), $\text{C}_{26}\text{H}_{23}^{37}\text{ClNO}_7$ [M + H]⁺, m/z : 498.1129.

3.1.4 Spectral data of compound 1d, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H,8H*-pyrano[3,2-*g*]chromen-5-yl 3-chloro-4-fluorobenzoate

Nordentatin (108.2 mg, 0.3467 mmol), 3-chloro-4-fluorobenzoyl chloride (100.3 mg, 0.5201 mmol), yield 54.5%. UV (MeOH), λ_{\max} (log ϵ) 340 (0.772), 268 (1.703), 233 (1.952), 233 (1.952). M.p. 173–174°C. FT-IR 3,086, 3,049, 2,970, 2,935, 2,922, 1,747, 1,720, 1,618, 1,598, 1,548 cm⁻¹. ^1H NMR (chloroform-*d*, 600 MHz) δ 8.33 (1H, dd, J = 6.9, 2.1 Hz), 8.16 (1H, ddd, J = 8.5, 4.5, 2.2 Hz), 7.52 (1H, d, J = 9.7 Hz), 7.34 (1H, t, J = 8.5 Hz), 6.33 (1H, dd, J = 17.4, 10.6 Hz), 6.24 (1H, d, J = 10.0 Hz), 6.20 (1H, d, J = 9.7 Hz), 5.71 (1H, d, J = 10.0 Hz), 4.98 (1H, d, J = 17.4 Hz), 4.94–4.90 (1H, m), 1.70 (6H, s), 1.48 (6H, s). ^{13}C NMR data (see the supplementary material). DART-MS, $\text{C}_{26}\text{H}_{23}\text{ClFO}_5$, m/z : 469.1221 [M + H]⁺ (calcd mass for $\text{C}_{26}\text{H}_{23}\text{ClFO}_5$, m/z : 469.1218), $\text{C}_{26}\text{H}_{23}^{37}\text{ClFO}_5$ [M + H]⁺, m/z : 471.1191.

3.1.5 Spectral data of compound 1e, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H,8H*-pyrano[3,2-*g*]chromen-5-yl 3-bromobenzoate

Nordentatin (104.8 mg, 0.3358 mmol), 3-bromo-benzoyl chloride (110.5 mg, 0.5037 mmol), yield 93.5%. UV (MeOH),

λ_{\max} (log ϵ) 340 (0.782), 268 (1.811), 209 (4.0). M.p. 127–128°C. FT-IR 3,080, 2,964, 2,935, 2,883, 1,741, 1,724, 1,620, 1,602, 1,554 cm⁻¹. ^1H NMR (chloroform-*d*, 600 MHz) δ 8.32 (1H, dd, J = 1.7 Hz), 8.12 (1H, dt, J = 7.8, 1.3 Hz), 7.90 (1H, ddd, J = 8.0, 2.0, 1.0 Hz), 7.54 (1H, d, J = 9.7 Hz), 7.41 (1H, dt, J = 7.9 Hz), 6.33 (1H, dd, J = 17.4, 10.6 Hz), 6.26 (1H, d, J = 10.0 Hz), 6.21 (1H, d, J = 9.7 Hz), 5.70 (1H, d, J = 10.0 Hz), 4.98 (1H, dd, J = 17.4, 1.0 Hz), 4.92 (1H, dd, J = 10.6, 1.0 Hz), 1.70 (6H, s), 1.48 (6H, s). ^{13}C NMR data (see the supplementary material). DART-MS, $\text{C}_{26}\text{H}_{24}\text{BrO}_5$, m/z : 495.0802 [M + H]⁺ (calcd mass for $\text{C}_{26}\text{H}_{24}\text{BrO}_5$, m/z : 495.0807), $\text{C}_{26}\text{H}_{24}^{81}\text{BrO}_5$ [M + H]⁺, m/z : 497.0779.

3.1.6 Spectral data of compound 1f, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H,8H*-pyrano[3,2-*g*]chromen-5-yl 4-butylbenzoate

Nordentatin (113.6 mg, 0.3467 mmol), 4-butylbenzoyl chloride (107.4 mg, 0.5461 mmol), yield 37%. UV (MeOH), λ_{\max} (log ϵ) 349 (0.79), 257 (2.87), 231 (1.0). M.p. 77–78°C. ^1H NMR (chloroform-*d*, 600 MHz), δ 2 \times 8.16 (1H, d, J = 8.3 Hz), 7.57 (1H, d, J = 9.7 Hz), 2 \times 7.37 (1H, d, J = 8.3 Hz), 6.34 (1H, dd, J = 17.4, 10.6 Hz), 6.17 (1H, d, J = 9.7 Hz), 5.67 (1H, d, J = 10.0 Hz), 4.98 (1H, dd, J = 17.4, 1.0 Hz), 4.91 (1H, dd, J = 10.6, 1.0 Hz), 2.79–2.67 (2H, m), 1.70 (6H, s), 1.67 (4H, tt, J = 8.9, 7.6 Hz), 1.47 (6H, s), 1.40 (2H, dq, J = 14.7, 7.4 Hz), 0.96 (3H, t, J = 7.4 Hz). ^{13}C NMR data (see the supplementary material). DART-MS, $\text{C}_{30}\text{H}_{33}\text{O}_5$, m/z 473.2328 [M + H]⁺ (calcd mass for $\text{C}_{30}\text{H}_{33}\text{O}_5$, m/z : 473.2328).

3.1.7 Spectral data of compound 1g, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H,8H*-pyrano[3,2-*g*]chromen-5-yl 2,4,6-trichlorobenzoate

Nordentatin (107.6 mg, 0.3448 mmol), 2,4,6-trichlorobenzoyl chloride (126.1 mg, 0.5172 mmol) yield 90%. UV (MeOH), λ_{\max} (log ϵ , MeOH), 349 (0.396), 267 (0.949), 259 (0.868). M.p. 149–150°C. FT-IR 3,093, 3,078, 2,999, 2,980, 2,929, 1,762, 1,728, 1,614, 1,600, 1,579, 1,550 cm⁻¹. ^1H NMR (chloroform-*d*, 600 MHz), δ 7.93 (1H, d, J = 9.7 Hz), 7.50 (2H, s), 6.65 (1H, d, J = 10.0 Hz), 6.32 (1H, dd, J = 17.4, 10.6 Hz), 6.24 (1H, d, J = 9.7 Hz), 5.77 (1H, d, J = 10.0 Hz), 4.97 (1H, dd, J = 17.4, 0.9 Hz), 4.91 (1H, dd, J = 10.6, 1.0 Hz), 1.70 (6H, s), 1.49 (6H, s). ^{13}C NMR data (see the supplementary material). DART-MS, $\text{C}_{26}\text{H}_{22}\text{Cl}_3\text{O}_5$, m/z : 519.0536 [M + H]⁺ (calcd mass for $\text{C}_{26}\text{H}_{22}\text{Cl}_3\text{O}_5$, m/z : 519.0533), $\text{C}_{26}\text{H}_{22}^{37}\text{ClCl}_2\text{O}_5$ [M + H]⁺,

m/z: 521.0505, $C_{26}H_{22}^{37}Cl_2ClO_5$ [M + H]⁺, *m/z*: 523.0471, $C_{26}H_{22}^{37}Cl_3O_5$ [M + H]⁺, *m/z*: 525.0438.

3.1.8 Spectral data of compound 1h, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H,8H*-pyrano[3,2-*g*]chromen-5-yl 3-(trifluoromethyl)benzoate

Nordentatin (110.7 mg, 0.3548 mmol), 3-(trifluoromethyl)benzoyl chloride (110.9 mg, 0.5322 mmol), yield 65.4%. UV (MeOH), λ_{max} (log ϵ) 352 (1.078), 272 (3.769), 228 (4.0), 209 (2.085). M.p. 77–78°C. FT-IR 3,095, 3,080, 2,966, 2,937, 2,924, 2,883, 1,747, 1,728, 1,620, 1,602, 1,552 cm⁻¹. ¹H NMR (chloroform-*d*, 600 MHz) δ 8.51 (1H, s), 8.45 (1H, d, *J* = 7.8 Hz), 7.98 (1H, d, *J* = 7.9 Hz), 7.74 (1H, t, *J* = 7.8 Hz), 7.54 (1H, d, *J* = 9.7 Hz), 6.34 (1H, dd, *J* = 17.4, 10.6 Hz), 6.26 (1H, d, *J* = 10.0 Hz), 6.20 (1H, d, *J* = 9.7 Hz), 5.71 (1H, d, *J* = 10.0 Hz), 5.02–4.96 (1H, m), 4.95–4.89 (1H, m), 1.71 (6H, s), 1.48 (6H, s). ¹³C NMR data (see the supplementary material). DART-MS, $C_{27}H_{24}F_3O_5$, *m/z*: 485.1571 [M + H]⁺ (calcd mass for $C_{27}H_{24}F_3O_5$, *m/z*: 485.1576).

3.1.9 Spectral data of compound 1i, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H,8H*-pyrano[3,2-*g*]chromen-5-yl 3,5-bis(trifluoromethyl)benzoate

Nordentatin (103.6 mg, 0.33205 mmol), 3,5-bis(trifluoromethyl)benzoyl chloride (121.6 mg, 0.5500 mmol), yield 41%. UV (MeOH), λ_{max} (log ϵ) 349 (0.79), 257 (2.87), 231 (1.0). M.p. 186–187°C. FT-IR 3,089, 3,066, 2,999, 2,981, 2,937, 1,759, 1,737, 1,620, 1,604, 1,552 cm⁻¹. ¹H NMR (chloroform-*d*, 600 MHz) δ 8.69 (2H, s), 8.22 (1H, s), 7.51 (1H, d, *J* = 9.7 Hz), 6.33 (1H, dd, *J* = 17.4, 10.6 Hz), 6.23 (1H, d, *J* = 10.0 Hz), 6.21 (1H, d, *J* = 9.7 Hz), 5.73 (1H, d, *J* = 10.0 Hz), 4.99 (1H, dd, *J* = 17.4, 0.8 Hz), 4.93 (1H, dd, *J* = 10.6, 0.9 Hz), 1.71 (6H, s), 1.49 (6H, s). ¹³C NMR data (see the supplementary material). DART-MS $C_{28}H_{23}F_6O_5$, *m/z*: 553.1440 [M + H]⁺ (calcd mass for $C_{28}H_{23}F_6O_5$, *m/z*: 553.1450).

3.1.10 Spectral data of compound 1j, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo-2*H,8H*-pyrano[3,2-*g*]chromen-5-yl 4-iodobenzoate

Nordentatin (103.0 mg, 0.3301 mmol), 4-iodobenzoyl chloride (131.8 mg, 0.4952 mmol), yield 58%. UV (MeOH), λ_{max} (log ϵ) 349 (0.79), 257 (2.87), 231 (1.0). M.p. 156–157°C. FT-IR 3,072, 2,972, 2,927, 2,870, 1,747,

1,730, 1,643, 1,614, 1,587 cm⁻¹. ¹H NMR (chloroform-*d*, 600 MHz) δ 7.95 (4H, s), 7.52 (1H, d, *J* = 9.7 Hz), 6.33 (1H, dd, *J* = 17.4, 10.6 Hz), 6.25 (1H, d, *J* = 10.0 Hz), 6.19 (1H, d, *J* = 9.7 Hz), 5.69 (1H, d, *J* = 10.0 Hz), 4.98 (1H, dd, *J* = 17.4, 0.9 Hz), 4.91 (1H, dd, *J* = 10.6, 1.0 Hz), 1.70 (6H, s), 1.47 (6H, s). ¹³C NMR data (see the supplementary material). DART-MS, $C_{26}H_{24}IO_5$, *m/z*: 543.0667 [M + H]⁺ (calcd mass for $C_{26}H_{24}IO_5$, *m/z*: 543.0668).

3.2 α -Glucosidase inhibition activity of nordentatin (1) and its derivatives (1a–1j)

All the compounds were evaluated for their inhibitory effect on yeast α -glucosidase (Table 1). Among the modified compounds, **1b**, **1d**, **1e**, **1f**, **1h**, **1i**, and **1j** exhibited a high inhibition of α -glucosidase with IC_{50} values of 1.54, 9.05, 4.87, 20.25, 12.34, 5.67, and 2.43 mM (acarbose 7.57 mM) (Table 1) [23]. The highest inhibition activity was shown when chloride was at the *meta*-position as in **1b**, followed by *para*-substituted iodide (**1j**) and the *meta*-position of bromide (**1e**). They are also comparable with the standard control acarbose. In addition, compounds containing bis(trifluoromethane) (**1i**), trifluoromethane (**1h**), 3-chloro, 5-fluoro (**1d**), and *para*-butyl groups (**1f**) showed higher activity than nordentatin (**1**) with an IC_{50} value of 36.7 mM. Based on this study, we can conclude that the activity of some compounds increased after modification, while that of some compounds decreased, e.g., **1a**, **1c**, and **1g** showed no inhibition.

Table 1: Results of α -glucosidase inhibition assay of derivatives **1a**–**1j**

Compound no.	IC_{50} (mM) Yeast α -glucosidase
1a	NI*
1b	1.54
1c	NI*
1d	9.05
1e	4.87
1f	20.25
1g	NI*
1h	12.34
1i	5.67
1j	2.43
1	36.7
Acarbose (std)	7.57

NI* = no inhibition at concentration \leq 5 mg/mL

Table 2: Investigation of the cytotoxicity of the modified compounds (**1a–1j**) against HeLa and T47D cell lines

Compound name	IC ₅₀ (mM)	
	HeLa	T47D
1a	0.45	0.10
1b	0.39	0.04
1c	0.40	0.24
1d	0.28	0.11
1e	0.59	0.12
1f	1.25	1.57
1g	0.52	0.41
1h	0.34	0.38
1i	0.25	0.24
1j	0.35	0.23
1	0.61	0.04
Doxorubicin	0.4 × 10 ⁻²	0.6 × 10 ⁻⁴

3.3 Cytotoxic activity of nordinatin (**1**) and modified compounds (**1a–1j**) against HeLa and T47D cell lines

The cytotoxicity of all modified compounds was tested against a HeLa cell line, and their IC₅₀ values were compared with those of nordinatin (**1**) and the standard control doxorubicin (Table 2). All tested compounds showed low activity with IC₅₀ values ranging from 0.25 to 1.25 mM against HeLa cells.

However, the results indicated that the modified compounds that contain fluorobenzoyl groups (**1i**, **1d**, **1h**, and **1b**) have more cytotoxic activity than others and nordinatin (**1**). On the other hand, the activity of compounds **1j**, **1c**, **1a**, **1g**, **1e**, and **1f** was lower (Table 2). The investigation of cell proliferation of modified compounds was also performed on a T47D cell line (Table 2). The results revealed that the modified compounds have moderate to low inhibition against the cancer cell line with the IC₅₀ values ranging from 0.043 to 1.57 mM, but their activity was lower than the activity of the parent compound, nordinatin (**1**) with an IC₅₀ value of 0.041 mM (Table 2). The structure–activity relationship study showed that the modified compounds with chloro and bromo compounds at *meta* and *para* positions had stronger inhibition than others.

4 Conclusions

In the current work, we continue our previous research concerning bioactive secondary metabolites from natural

medicinal plants and their derivatives. As a result, ten new pyranocoumarin benzoate derivatives were semi-synthesized in good to excellent yields from natural nordinatin (**1**) by an acylation method. Both parent and modified compounds were tested for their antidiabetic activity by an α-glucosidase assay and anticancer activity (HeLa and T47D cell lines) by an MTT assay. Among the tested compounds, modified compound **1b** showed the highest inhibition activity against yeast α-glucosidase enzymes, in particular 5 times higher than that of acarbose and 20 times higher than that of the parent compound, nordinatin (**1**). Among the tested compounds, modified compound **1i** showed the highest cytotoxic activity against the HeLa cell line. Compound **1b** showed a moderate cytotoxic activity against T47D but it was less effective than the parent compound, nordinatin (**1**). As a result of this study, we can conclude that some modified compounds are promising, since their activity is comparable with that of standard drugs. Especially, active compound **1b**, 2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxo2H,8H-pyranopyrano[3,2-g]chromen-5-yl-3-chlorobenzoate, should be studied as a potential alternative α-glucosidase inhibitor.

Acknowledgements: The authors would like to thank (1) Universitas Airlangga for Airlangga Development Scholarship (ADS), (2) Riset Mandat Grand of Universitas Airlangga that has funded this research, (3) Faculty of Pharmacy, Meijo University, Nagoya, Japan, for measuring NMR and HRMS data, and (4) Dr. Kaido Simon and Prof. M. Iqbal Chaudhary for editing this manuscript.

Conflict of interest: The authors declare no conflict of interest.

References

- [1] Kongkathip N, Kongkathip B. Constituents and bioactivities of *Clausena excavata*. *Heterocycles*. 2009;79(C):121–44.
- [2] Thant TM, Aminah NS, Kristanti AN, Ramadhan R, Phuwapraisirisan P, Takaya Y. A new pyranocoumarin from *Clausena excavata* roots displaying dual inhibition against α-glucosidase and free radical. *Nat Prod Res*. 2019; 1–6.
- [3] Takemura Y, Nakamura K, Hirusawa T, Ju-ichi M, Ito C, Furukawa H. Four new furanone-coumarins from *Clausena excavata*. *Chem Pharm Bull (Tokyo)*. 2000;48(4):582–4.
- [4] Taufiq-Yap YH, et al. A new cytotoxic carbazole alkaloid from *Clausena excavata*. *Nat Prod Res*. 2007;21(9):310–3.
- [5] Kumar R, Saha A, Saha D. A new antifungal coumarin from *Clausena excavata*. *Fitoterapia*. 2012;83(1):230–3.

- [6] Lipeeva AV, et al. Design, synthesis and antibacterial activity of coumarin-1,2,3-triazole hybrids obtained from natural furocoumarin peucedanin. 2019;24:1–23.
- [7] Davorka Z, Muratovic S, Makuc D, Plavec J, Cetina M, Nagl A, et al. Benzylidene-bis-(4-hydroxycoumarin) and benzopyranocoumarin derivatives: synthesis, ¹H/¹³C-NMR conformational and X-ray crystal structure studies and *in vitro* antiviral activity evaluations. *Molecules*. 2011;16(7):6023–40.
- [8] Noipha K, Thongthoom T, Songsiang U, Boonyarat C, Yenjai C. Carbazoles and coumarins from *Clausena harmandiana* stimulate glucose uptake in L6 myotubes. *Diabetes Res Clin Pract*. 2010;90(3):67–71.
- [9] Flores-Bocanegra L, González-Andrade M, Bye R, Linares E, Mata R. α -Glucosidase inhibitors from *Salvia cincinata*. *J Nat Prod*. 2017;80(5):1584–93.
- [10] Gothai S, Ganesan P, Park SY, Fakurazi S, Choi DK, Arulselvan P. Natural phyto-bioactive compounds for the treatment of type 2 diabetes: Inflammation as a target. *Nutrients*. 2016;8(8):461–38.
- [11] Bathula C, Mamidala R, Thulluri C, Agarwal R, Jha KK, Munshi P, et al. Substituted furopyridinediones as novel inhibitors of α -glucosidase. *RSC Adv*. 2015;5:90374–85.
- [12] Du ZY, et al. α -Glucosidase inhibition of natural curcuminoids and curcumin analogs. *Eur J Med Chem*. 2006;41(2):213–8.
- [13] Taha M, et al. Synthesis of novel triazinoindole-based thiourea hybrid: a study on α -glucosidase inhibitors and their molecular docking. *Molecules*. 2019;24:1–16.
- [14] Zhao X, et al. Resveratrololide alleviates postprandial hyperglycemia in diabetic mice by competitively inhibiting α -glucosidase. *J Agric Food Chem*. 2019;67(10):2886–93.
- [15] Santana FR, et al. Evaluation of the cytotoxicity on breast cancer cell of extracts and compounds isolated from *Hyptis pectinata* (L.) poit. *Nat Prod Res*. 2020;34(1):102–9.
- [16] Potikanond S, et al. *Kaempferia parviflora* extract exhibits anti-cancer activity against HeLa cervical cancer cells. *Front Pharmacol*. 2017;8(Sep):1–12.
- [17] Chattopadhyay S, Bisaria VS, Panda AK, Srivastava AK. Cytotoxicity of *in vitro* produced podophyllotoxin from *Podophyllum hexandrum* on human cancer cell line. *Nat Prod Res*. 2004;18(1):51–7.
- [18] Novakovic M, Simic S, Koracak L, Zlatovic M, Ilic-Tomic T, Asakawa Y, et al. Chemo- and biocatalytic esterification of marchantin A and cytotoxic activity of ester derivatives. *Fitoterapia*. 2020;142:104520.
- [19] Wu CZ, et al. Synthesis and evaluation of bakuchiol derivatives as potential anticancer agents. *Molecules*. 2018; 23(3):1–12.
- [20] Pena MJ, Botubol-Ares JM, nJames Hanson R, Galan RH, Collado IG. Efficient o-acylation of alcohols and ohenol using Cp₂TiCl as a reaction promoter. *Eur J Org Chem*. 2016;2016(21):3584–91.
- [21] Ramadhan R, Worawalai W, Phuwapraisirisan P. New onoceranoid xyloside from *Lansium parasiticum*. *Nat Prod Res*. 2019;33(20):2917–24.
- [22] Suwito H, Hardiyanti HD, Ul Haq K, Kristanti AN, Khasanah M. (*E*)-3-[3-(4-Morpholinophenyl)acryloyl]-2H-chromen-2-one. *Molbank*. 2018;2018(4):1–5.
- [23] Choi CW, et al. Yeast α -glucosidase inhibition by isoflavones from plants of leguminosae as an *in vitro* alternative to acarbose. *J Agric Food Chem*. 2010;58(18):9988–93.